A Phase 3 interventional study of Pemetrexed and Cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 42nd largest by enrollment of the 223 interventional ones that give a count, is one of 21 that started in 2009, is one of 44 in phase 3, and was the 99th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 21 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 236 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 35th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2009, is one of 25 in phase 3, and was the 77th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants. Half of the participants will receive chemotherapy (pemetrexed/cisplatin) followed by an oral anti-cancer agent (gefitinib) and the other half of the participants will receive only the oral anti-cancer agent (gefitinib).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must be "light ex-smokers" or "never-smokers".
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed · Drug: Cisplatin · Drug: Gefitinib
Drug: Gefitinib
500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
Also known as: Alimta, LY231514
75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
Progression Free Survival (PFS)
PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.
Time frame: Randomization to the first date of measured PD or death up to 37.32 months
Overall Survival (OS)
OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).
Time frame: Randomization up to date of death from any cause up to 57.13 months
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.
Time frame: Randomization up to 37.52 months
Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]
DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.
Time frame: Randomization up to 37.52 months
Time to Progressive Disease (TtPD)
TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.
Time frame: Randomization to the first date of measured PD up to 37.32 months
Duration of Tumor Response
The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.
Time frame: Date of initial response to the date of measured PD or death up to 34.43 months
Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)
The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.
Time frame: Every cycle while on-study therapy and at 3 months post last dose
| Milestone | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Started | 118 | 118 |
| Received at least 1 dose of study drug | 114 | 118 |
| Completed | 88 | 92 |
| Not completed | 30 | 26 |
| Withdrew: Withdrawal by subject | 23 | 20 |
| Withdrew: Sponsor decision | 3 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Physician decision | 1 | 3 |
PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date.
| months | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Progression Free Survival (PFS) | 8.38 (6.44 to 11.14) | 9.63 (6.74 to 11.10) |
OS was the duration from randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date for a particular analysis, OS was censored at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date included adverse event date, lesion assessment date, visit date, and last known alive date).
| months | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Overall Survival (OS) | 26.87 (20.76 to 35.12) | 27.86 (21.26 to 31.36) |
TRR was defined as the percentage of randomized participants having a best overall study response of CR or PR using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all target lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and the appearance of no new lesions.
| percentage of participants | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] | 41.5 (32.5 to 51.0) | 47.5 (38.2 to 56.9) |
DCR was defined as the percentage of randomized participants with overall response of CR, PR or SD using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. CR was defined as the disappearance of all tumor lesions; PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared; SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD. PD defined as at least 20% increase in the sum of LD of target, lesions taking as reference, the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions or progression of nontarget lesions.
| percentage of participants | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] | 71.2 (62.1 to 79.2) | 64.4 (55.1 to 73.0) |
TtPD was defined as the time from randomization to the first date of objectively determined progressive disease (PD). For participants who were not known to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, or who had died without objective progression of disease, TtPD was censored at the date of the participant's last objective progression-free disease assessment prior to cut-off date.
| months | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Time to Progressive Disease (TtPD) | 8.61 (6.60 to 11.20) | 9.69 (6.87 to 11.20) |
The duration of a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria was defined as the time from first objective status assessment of CR or PR to the first time of objective disease progression or death as a result of any cause. CR was defined as the disappearance of all tumor lesions. PR was defined as at least a 30% decrease in sum of longest diameter (LD) of target lesions taking as reference the baseline sum of LDs or complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions and no new lesions having appeared. Participants who were not known to have died or had objective progression of disease as of the data-inclusion cut-off date were censored at the date of the participant's last complete objective progression-free disease assessment prior to that cut-off date.
| months | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Duration of Tumor Response | 12.09 (7.16 to 22.11) | 11.93 (9.63 to 14.09) |
The LCSS data included participant ratings of 6 symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) and 3 summary items (overall symptom severity, interference with daily activities, and overall QoL). Participants recorded their ratings for each item, by placing a mark on a visual analog scale (VAS) that ranged from 0 millimeter (mm) (lower symptom burden, less interference with normal activity, or better QoL) to 100 mm (higher symptom burden, more interference with normal activity, or worse QoL). TWQ was evaluated from date of randomization to first date of worsening, defined as a half standard deviation change as determined from the corresponding baseline item score in the pooled treatment group. For participants not known to have worsened or who were lost to follow-up, TWQ was censored at date of the participant's last LCSS assessment.
| months | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| Loss of appetite | 2.99 (1.71 to 3.68) | 7.95 (4.90 to NA) |
| Fatigue | 4.83 (2.92 to 6.83) | 7.29 (3.75 to 13.63) |
| Cough | 8.57 (5.68 to 10.94) | 16.69 (6.51 to NA) |
| Dyspnea | 6.97 (3.15 to 15.44) | 18.23 (7.06 to NA) |
| Hemoptysis | 19.45 (9.89 to NA) | 17.05 (10.02 to NA) |
| Pain | 6.44 (2.92 to 11.40) | 15.57 (9.95 to NA) |
| Overall symptoms | 4.76 (3.12 to 12.81) | 13.63 (7.06 to NA) |
| Interference | 4.50 (3.02 to 7.03) | 8.34 (4.90 to NA) |
| Overall quality of life | 6.14 (3.52 to 12.78) | 6.93 (3.22 to 13.63) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin + Gefitinib | — | 35/114 (30.7%) | 111/114 (97.4%) |
| Gefitinib | — | 32/118 (27.1%) | 110/118 (93.2%) |
| Event | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| PneumoniaInfections and infestations | 7/114 | 9/118 |
| VomitingGastrointestinal disorders | 4/114 | 0/118 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/114 | 4/118 |
| PyrexiaGeneral disorders | 3/114 | 1/118 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/114 | 3/118 |
| DiarrhoeaGastrointestinal disorders | 2/114 | 2/118 |
| AstheniaGeneral disorders | 2/114 | 0/118 |
| FatigueGeneral disorders | 2/114 | 1/118 |
| Septic shockInfections and infestations | 2/114 | 0/118 |
| Urinary tract infectionInfections and infestations | 2/114 | 0/118 |
| Event | Pemetrexed + Cisplatin + Gefitinib | Gefitinib |
|---|---|---|
| NauseaGastrointestinal disorders | 70/114 | 26/118 |
| RashSkin and subcutaneous tissue disorders | 36/114 | 52/118 |
| DiarrhoeaGastrointestinal disorders | 30/114 | 50/118 |
| Decreased appetiteMetabolism and nutrition disorders | 43/114 | 29/118 |
| VomitingGastrointestinal disorders | 41/114 | 13/118 |
| PruritusSkin and subcutaneous tissue disorders | 34/114 | 38/118 |
| ConstipationGastrointestinal disorders | 36/114 | 15/118 |
| FatigueGeneral disorders | 32/114 | 21/118 |
| Alanine aminotransferase increasedInvestigations | 20/114 | 30/118 |
| CoughRespiratory, thoracic and mediastinal disorders | 25/114 | 21/118 |
All randomized participants.
| Age, Continuous(years) | Pemetrexed + Cisplatin + Gefitinib | Gefitinib | Total |
|---|---|---|---|
| Mean | 58.53 ± 10.730 | 59.36 ± 10.672 | 58.95 ± 10.686 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin + Gefitinib | Gefitinib | Total |
|---|---|---|---|
| Female | 88 | 89 | 177 |
| Male | 30 | 29 | 59 |
| Race/Ethnicity, Customized(participant) | Pemetrexed + Cisplatin + Gefitinib | Gefitinib | Total |
|---|---|---|---|
| Asian | 118 | 118 | 236 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin + Gefitinib | Gefitinib | Total |
|---|---|---|---|
| Hong Kong | 3 | 7 | 10 |
| Taiwan | 39 | 28 | 67 |
| Thailand | 21 | 22 | 43 |
| Singapore | 1 | 1 | 2 |
| Korea, Republic of | 54 | 60 | 114 |
The record gives a start of Nov 2009, a primary completion of Apr 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →